Michelle Mierzwa

Michelle Mierzwa

Auto-generated profile, based on publicly available information

Michelle Mierzwa

Department of Radiation Oncology University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CPCindy Perez-Pacheco
Cindy Perez-Pacheco
LSLigia B. Schmitd
Ligia B. Schmitd
AFAllison Furgal
Allison Furgal
EBEmily L. Bellile
Emily L. Bellile
MLMin Liu
Min Liu
NDNisha J. D'SIlva
Nisha J. D'SIlva
Purpose: Perineural invasion (PNI) in oral cavity squamous cell carcinoma (OSCC) is associated with poor survival. Because of the risk of recurrence, patients with PNI receive additional therapies after surgical resection. Mechanistic studies have shown that nerves in the tumor microenvironment promote aggressive tumor growth. Therefore, in this study, we evaluated whether nerve density (ND) influences tumor growth and patient survival. Moreover, we assessed the reliability of artificial intelligence (AI) in evaluating ND. Experimental Design: To investigate whether increased ND in OSCC influences patient outcome, we performed survival analyses. Tissue sections of OSCC from 142 patients were stained with hematoxylin and eosin and IHC stains to detect nerves and tumor. ND within the tumor bulk and in the adjacent 2 mm was quantified; normalized ND (NND; bulk ND/adjacent ND) was calculated. The impact of ND on tumor growth was evaluated in chick chorioallantoic-dorsal root ganglia (CAM-DRG) and murine surgical denervation models. Cancer cells were grafted and tumor size quantified. Automated nerve detection, applying the Halo AI platform, was compared with manual assessment. Results: Disease-specific survival decreased with higher intratumoral ND and NND in tongue SCC. Moreover, NND was associated with worst pattern-of-invasion and PNI. Increasing the number of DRG, in the CAM-DRG model, increased tumor size. Reduction of ND by denervation in a murine model decreased tumor growth. Automated and manual detection of nerves showed high concordance, with an F1 score of 0.977. Conclusions: High ND enhances tumor growth, and NND is an important prognostic factor that could influence treatment selection for aggressive OSCC. See related commentary by Hondermarck and Jiang, p. 2342

18 October 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
SGShuchi Gulati
Shuchi Gulati
JDJanki Mihir Desai
Janki Mihir Desai
SPSarah M. Palackdharry
Sarah M. Palackdharry
JMJohn C. Morris
John C. Morris
ZZZheng Zhu
Zheng Zhu
TWTrisha Wise-Draper
Trisha Wise-Draper

1 December 2020 in Oral Oncology
Verified
Journal Article
Closed access
LGLaila A. Gharzai
Laila A. Gharzai
PLPin Li
Pin Li
MSMatthew J. Schipper
Matthew J. Schipper
JYJohn Yao
John Yao
CMCharles S. Mayo
Charles S. Mayo
MMMichelle Mierzwa
Michelle Mierzwa

15 September 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMichelle L. Mierzwa
Michelle L. Mierzwa
MAMadhava Aryal
Madhava Aryal
CLChoonik Lee
Choonik Lee
MSMatthew Schipper
Matthew Schipper
MVMonica VanTil
Monica VanTil
YCYue Cao
Yue Cao
Purpose: We conducted a randomized phase II multicenter clinical trial to test the hypothesis that physiologic MRI-based radiotherapy (RT) dose escalation would improve the outcome of patients with poor prognosis head and neck cancer. Patients and Methods: MRI was acquired at baseline and at RT fraction 10 to create low blood volume/apparent diffusion coefficient maps for RT boost subvolume definition in gross tumor volume. Patients were randomized to receive 70 Gy (standard RT) or 80 Gy to the boost subvolume (RT boost) with concurrent weekly platinum. The primary endpoint was disease-free survival (DFS) with significance defined at a one-sided 0.1 level, and secondary endpoints included locoregional failure (LRF), overall survival (OS), comparison of adverse events and patient reported outcomes (PRO). Results: Among 81 randomized patients, neither the primary endpoint of DFS (HR = 0.849, P = 0.31) nor OS (HR = 1.19, P = 0.66) was significantly improved in the RT boost arm. However, the incidence of LRF was significantly improved with the addition of the RT boost (HR = 0.43, P = 0.047). Two-year estimates [90% confidence interval (CI)] of the cumulative incidence of LRF were 40% (27%–53%) in the standard RT arm and 18% (10%–31%) in the RT boost arm. Two-year estimates (90% CI) for DFS were 48% (34%–60%) in the standard RT arm and 57% (43%–69%) in the RT boost arm. There were no significant differences in toxicity or longitudinal differences seen in EORTC QLQ30/HN35 subscales between treatment arms in linear mixed-effects models. Conclusions: Physiologic MRI-based RT boost decreased LRF without a significant increase in grade 3+ toxicity or longitudinal PRO differences, but did not significantly improve DFS or OS. Additional improvements in systemic therapy are likely necessary to realize improvements in DFS and OS.

12 December 2018 in Head & Neck
Verified
Journal Article
Open access
PDF file
TCThong Chotchutipan
Thong Chotchutipan
BRBenjamin S. Rosen
Benjamin S. Rosen
PHPeter G. Hawkins
Peter G. Hawkins
JLJae Y. Lee
Jae Y. Lee
ASAnjali L. Saripalli
Anjali L. Saripalli
MMMichelle L. Mierzwa
Michelle L. Mierzwa
Background: We sought to investigate the prognostic value of volumetric positron emission tomography (PET) parameters in patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC) and a ≤10 pack‐year smoking history treated with chemoradiation.Methods: A total of 142 patients were included. Maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of the primary tumor, involved regional lymph nodes, and total lesion were calculated. Cox proportional hazard modeling was used to evaluate associations of clinical and PET parameters with locoregional failure‐free survival (LRFFS), distant metastasis‐free survival (DMFS), and overall survival (OS).Results: On univariate analysis, volumetric PET parameters were significantly associated with all endpoints, and 8th edition American Joint Committee on Cancer/Union Internationale Contre le Cancer staging was significantly associated with DMFS and OS. On multivariate analysis, total lesion TLG was significantly associated with LRFFS, while staging was most significantly prognostic for DMFS and OS.Conclusion: Volumetric PET parameters are uniquely prognostic of LRFFS in low‐risk HPV‐related OPSCC and may be useful for directing de‐intensification strategies.

15 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
CBChandan Bhambhani
Chandan Bhambhani
QKQing Kang
Qing Kang
DHDaniel H. Hovelson
Daniel H. Hovelson
ESErin Sandford
Erin Sandford
MOMary Olesnavich
Mary Olesnavich
MTMuneesh Tewari
Muneesh Tewari
BACKGROUND: Transrenal cell-free tumor DNA (TR-ctDNA), which transits from the bloodstream into urine, has the potential to enable noninvasive cancer detection for a wide variety of nonurologic cancer types. Methods: Using whole-genome sequencing, we discovered that urine TR-ctDNA fragments across multiple cancer types are predominantly ultrashort (<50 bp) and, therefore, likely to be missed by conventional ctDNA assays. We developed an ultrashort droplet digital PCR assay to detect TR-ctDNA originating from HPV-associated oropharyngeal squamous cell carcinoma (HPV + OPSCC) and confirmed that assaying ultrashort DNA is critical for sensitive cancer detection from urine samples. Results: TR-ctDNA was concordant with plasma ctDNA for cancer detection in patients with HPV + OPSCC. As proof of concept for using urine TR-ctDNA for posttreatment surveillance, in a small longitudinal case series, TR-ctDNA showed promise for noninvasive detection of recurrence of HPV + OPSCC. Conclusion: Our data indicate that focusing on ultrashort fragments of TR-ctDNA will be important for realizing the full potential of urine-based cancer diagnostics. This has implications for urine-based detection of a wide variety of cancer types and for facilitating access to care through at-home specimen collections. Funding: NIH grants R33 CA229023, R21 CA225493; NIH/National Cancer Institute grants U01 CA183848, R01 CA184153, and P30CA046592; American Cancer Society RSG-18-062-01-TBG; American Cancer Society Mission Boost grant MBGI-22-056-01-MBG; and the A. Alfred Taubman Medical Research Institute.